Neovasc Inc. Weighted Average Shares Growth

Weighted Average Shares Growth of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Weighted Average Shares Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Weighted Average Shares Growth for the quarter ending March 31, 2022 was 38.51% (a -78.03% decrease compared to previous quarter)
  • Year-over-year quarterly Weighted Average Shares Growth decreased by -91.49%
  • Annual Weighted Average Shares Growth for 2021 was 277.83% (a 78.18% increase from previous year)
  • Annual Weighted Average Shares Growth for 2020 was 155.93% (a -56.72% decrease from previous year)
  • Annual Weighted Average Shares Growth for 2019 was 360.25% (a -77.7% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Weighted Average Shares Growth of Neovasc Inc.

Most recent Weighted Average Shares Growthof NVCN including historical data for past 10 years.

Interactive Chart of Weighted Average Shares Growth of Neovasc Inc.

Neovasc Inc. Weighted Average Shares Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 38.51%
2021 175.3% 238.9% 452.45% 347.87% 277.83%
2020 277.35% 165.9% 79.24% 171.77% 155.93%
2019 360.25% 297.88% 407.82% -72.24% 360.25%
2018 1615.15% 2256.25% 1578.13% 18587.1% 1615.15%
2017 22.22% 18.52% 18.52% 14.81% 22.22%
2016 0.0% 0.0% 0.0% 8.0% 3.85%
2015 22.73% 22.73% 22.73% 31.58% 23.81%
2014 15.79% 15.79% 15.79% 5.56% 10.53%
2013 0.0% 5.56% 5.56% 0.0% 5.56%
2012 11.76% -4.58% -3.17% -0.44% 5.88%
2011 -9.75% -6.99%

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.